United Therapeutics Corporation (NASDAQ:UTHR) Receives $648.33 Consensus Target Price from Analysts

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $648.3333.

UTHR has been the subject of several recent analyst reports. Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company.

Insiders Place Their Bets

In related news, Director Jan Malcolm sold 325 shares of the stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $550.59, for a total transaction of $178,941.75. Following the completion of the sale, the director owned 450 shares in the company, valued at $247,765.50. This trade represents a 41.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $522.37, for a total value of $4,962,515.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $169,479,289.91. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 502,833 shares of company stock worth $279,377,162 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in UTHR. Handelsbanken Fonder AB boosted its holdings in United Therapeutics by 4.1% during the second quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company’s stock worth $7,109,000 after buying an additional 520 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab lifted its position in United Therapeutics by 7.4% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company’s stock valued at $5,992,000 after acquiring an additional 760 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of United Therapeutics by 79.2% during the second quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company’s stock worth $45,805,000 after buying an additional 37,355 shares during the period. GAMMA Investing LLC boosted its position in United Therapeutics by 10.3% during the 2nd quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company’s stock worth $958,000 after acquiring an additional 165 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in United Therapeutics by 93.6% in the second quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 88 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $525.82 on Tuesday. The stock has a market cap of $22.32 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.75 and a beta of 0.58. The business has a 50 day simple moving average of $544.65 and a 200 day simple moving average of $532.54. United Therapeutics has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.63 EPS. On average, analysts predict that United Therapeutics will post 26.65 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.